The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

Autor:	Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai, Jiunn-Tay Lee, Che-Sheng Chu, Ta-Chuan Yeh, Ming-Wei Su, Guan-Yu Lin, Yu-Kai Lin, Hsuan-Te Chu, Chia-Kuang Tsai, Fu-Chi Yang
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Cytokine Interleukin-33 Alzheimer’s disease Mild cognitive disorder Cognitive decline Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Zdroj:	Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-9 (2020)
Druh dokumentu:	article
ISSN:	1758-9193
DOI:	10.1186/s13195-020-00652-z
Popis:	Abstract Background The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association between human blood levels of IL-33 and cognitive preservation in amnestic mild cognitive impairment (aMCI) and AD. Methods A total of 100 participants (26 controls, 35 aMCI patients, and 39 AD patients) completed two Mini-Mental State Examinations (MMSEs) over a 1-year interval. In all 100 participants at the second MMSE, we examined the plasma levels of IL-33, IL-β, IL-1 receptor agonist (IL-1RA), beta amyloid (Aβ), and tau and apolipoprotein E (ApoE) genotyping; we also performed Hopkins Verbal Learning Test, Trail Making Test, forward and backward digit span, and Clinical Dementia Rating. Results IL-33 expression showed a positive trend among controls (1/26 = 3.8%), aMCI (9/35 = 25.7%), and AD (17/39 = 43.6%) (trend analysis: P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/b62986d3a46846209285ebf00b1c85bc Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.